Literature DB >> 16775574

Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice.

Lois W Brüggemann1, Saskia H H F Schoenmakers, Angelique P Groot, Pieter H Reitsma, C Arnold Spek.   

Abstract

OBJECTIVE: The factor V Leiden (FVL) mutation (Arg506Glu) results in the production of an FV protein that when activated is relatively resistant to inactivation by activated protein C and thereby leads to predisposition to thrombosis. The rather high prevalence of the FVL mutation in the general population prompted speculation about a potential survival benefit for individuals carrying the FVL allele. Indeed, both clinical and experimental animal data suggest that a heterozygous FVL genotype might protect against the lethal consequences of sepsis. We sought to confirm the survival advantage of heterozygous FVL mice in septic disease.
DESIGN: Controlled animal experiment.
SETTING: Academic research laboratory.
SUBJECTS: Wild-type, heterozygous, and homozygous FVL mice subjected to 1 x 10 live bacteria as model for septic peritonitis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The intraperitoneal injection of E. coli led to growth and dissemination of bacteria and provoked an inflammatory response as evident from elevated cytokine levels (interleukin-6, interleukin-10, and tumor necrosis factor-alpha), induced thrombin-antithrombin complex levels, increased granulocyte influx into the peritoneal cavity, liver necrosis, and adhesion of leukocytes to the vessel wall, resulting in approximately 50% mortality after 72 hrs. The FVL genotype had no significant effect on bacterial outgrowth, markers of inflammation (i.e., tumor necrosis factor-alpha levels of 152 [96.2-200], 152 [99.7-1745], and 110 [99.7-177] pg/mL in peritoneal lavage fluid at t = 20 hrs for wild-type, heterozygous, and homozygous FVL mice, respectively), thrombin generation (i.e., thrombin-antithrombin complex levels of 19.9 [9.31-37.4], 10.4 [6.55-15.8], and 12.6 [8.24-29.0] ng/mL in peritoneal lavage fluid at t = 6 hrs for wild-type, heterozygous, and homozygous FVL mice, respectively), and/or survival (50%, 36%, and 50% for wild-type, heterozygous, and homozygous FVL mice, respectively).
CONCLUSIONS: The FVL allele has no beneficial effect in mouse septic peritonitis, and the general protective effect of FVL in sepsis needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775574     DOI: 10.1097/01.CCM.0000228918.30931.E8

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

1.  Inflammation-associated activation of coagulation and immune regulation by the protein C pathway.

Authors:  Hartmut Weiler
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

2.  Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency.

Authors:  Angelina J Lay; Deborah Donahue; Meng-Ju Tsai; Francis J Castellino
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

3.  Survival advantage of heterozygous factor V Leiden carriers in murine sepsis.

Authors:  E Kerschen; I Hernandez; M Zogg; M Maas; H Weiler
Journal:  J Thromb Haemost       Date:  2015-03-31       Impact factor: 5.824

4.  Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies.

Authors:  H Sun
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

5.  Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study.

Authors:  Thomas Benfield; Karen Ejrnaes; Klaus Juul; Christian Østergaard; Jannik Helweg-Larsen; Nina Weis; Lea Munthe-Fog; Gitte Kronborg; Marianne Ring Andersen; Anne Tybjaerg-Hansen; Børge G Nordestgaard; Peter Garred
Journal:  Crit Care       Date:  2010-03-05       Impact factor: 9.097

6.  Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.

Authors:  Marcel Schouten; Cornelis van't Veer; Joris J T H Roelofs; Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

7.  Factor v leiden and inflammation.

Authors:  Silvia Perez-Pujol; Omer Aras; Gines Escolar
Journal:  Thrombosis       Date:  2012-05-14

Review 8.  Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective.

Authors:  Maiara Marx Luz Fiusa; Marco Antonio Carvalho-Filho; Joyce M Annichino-Bizzacchi; Erich V De Paula
Journal:  BMC Med       Date:  2015-05-06       Impact factor: 8.775

9.  Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders.

Authors:  Lois W Brüggemann; Henri H Versteeg; Tatjana M Niers; Pieter H Reitsma; C Arnold Spek
Journal:  J Cell Mol Med       Date:  2008-03-20       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.